ClinicalTrials.gg

Program

upacicalcet sodium hydrate

Also written as “PLS240” and “Open-Label Extension PLS240”.

Its studies are mostly in Hyperparathyroidism, Secondary · Renal Insufficiency, Chronic, led by Pathalys Pharma.

Furthest: phase 3, since Apr 17, 20233 company-led studies, 1 open or runningNext primary completion: Feb 22, 2032 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pathalys Pharma31 open or runningphase 3since Apr 17, 2023Apr 17, 2023Feb 22, 2032phase 3 · NCT07890584

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 17, 2023First studies: 2 phase 3 studies in Hyperparathyroidism, SecondaryFirst studyNCT05832931, NCT05836220
  2. Oct 16, 2026Phase 3 study in Renal Insufficiency, ChronicNCT07890584 · 56 planned · United States

Ahead

  1. Feb 22, 2032Primary completion: phase 3 study in Renal Insufficiency, ChronicNCT07890584

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07890584Renal Insufficiency, Chronic · United States3Not yet recruitingFeb 22, 203256
NCT05836220Hyperparathyroidism, Secondary · United States, Bulgaria, Poland and more3CompletedAug 5, 2025412
NCT05832931Hyperparathyroidism, Secondary · United States, Bulgaria, Poland and more3CompletedJul 28, 2025362

How it is read

Names in the registry

  • “PLS240”, 3 entries
  • “Open-Label Extension PLS240”, 2 entries

Codes read as this program: PLS240.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.